BioSpace News Archive

Greenstone Biosciences on a Quest for Duchenne Muscular Dystrophy Therapeutics with New Funding from CIRM

Recently, the California Institute of Regenerative Medicine (CIRM) awarded Greenstone Bio $675,000 to find novel treatments for Duchenne Muscular Dystrophy (DMD), a fatal genetic disease with no current cure.

February 1, 2023

·

1 min read

Biotech Bay

ORIC Pharmaceuticals to Participate in Upcoming February 2023 Investor Conferences

ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that management will participate in the following investor conferences in February.

February 1, 2023

·

1 min read

Business

Certara to Report Fourth Quarter and Full Year 2022 Financial Results on March 1st, 2023

Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the fourth quarter and full year of 2022 after the market close on Wednesday, March 1st, 2023.

February 1, 2023

·

1 min read

Business

BioSyent Declares First Quarter 2023 Dividend

BioSyent Inc. is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on March 15, 2023, to shareholders of record at the close of business on February 28, 2023.

February 1, 2023

·

1 min read

Bio NC

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 01, 2023

G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for 2,800 shares of G1’s common stock and 1,400 restricted stock units to one hired employee under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.

February 1, 2023

·

2 min read

Genetown

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 01, 2023

Cullinan Oncology, Inc. announced that the compensation committee of the Company’s Board of Directors granted stock option awards to purchase an aggregate of 56,000 shares of its common stock to three employees outside Cullinan Oncology, Inc’s 2021 Stock Option and Incentive Plan.

February 1, 2023

·

2 min read

STERIS Declares $0.47 per share Dividend - February 01, 2023

STERIS plc announced that the Company will distribute a quarterly interim dividend of $0.47 per share.

February 1, 2023

·

7 min read

Policy

Medexus Secures Public Reimbursement for Cuvposa® in Quebec

Medexus Pharmaceuticals wishes to inform investors that the company has reached an agreement with the provincial government of Quebec for government-sponsored coverage of Cuvposa.

February 1, 2023

·

7 min read

Biotech Beach

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - February 01, 2023

Zentalis™ Pharmaceuticals, Inc. announced that on February 1, 2023, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 12,500 shares of the Company’s common stock to one newly hired employee.

February 1, 2023

·

2 min read

Business

Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics

vTv Therapeutics Inc., a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes, announced the appointment of Elizabeth Keiley as Executive Vice President and General Counsel, effective immediately.

February 1, 2023

·

4 min read